Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease

A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS trial at ESC 2022.
Medscape Medical News

source https://www.medscape.com/viewarticle/979861?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost